WINTON GROUP Ltd Purchases 94,134 Shares of Exelixis, Inc. $EXEL

WINTON GROUP Ltd grew its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 1,651.5% in the second quarter, HoldingsChannel reports. The fund owned 99,834 shares of the biotechnology company’s stock after acquiring an additional 94,134 shares during the period. WINTON GROUP Ltd’s holdings in Exelixis were worth $5,432,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Motiv8 Investments LLC bought a new position in shares of Exelixis in the 4th quarter valued at about $26,000. Cassaday & Co Wealth Management LLC bought a new stake in Exelixis during the first quarter worth about $27,000. Western Wealth Management LLC acquired a new position in Exelixis during the first quarter valued at approximately $29,000. Acumen Wealth Advisors LLC acquired a new position in Exelixis during the fourth quarter valued at approximately $29,000. Finally, Northwestern Mutual Wealth Management Co. grew its stake in Exelixis by 1,380.4% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 829 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 773 shares in the last quarter. 85.27% of the stock is owned by institutional investors.

Exelixis Stock Performance

EXEL opened at $57.43 on Friday. Exelixis, Inc. has a fifty-two week low of $33.76 and a fifty-two week high of $59.72. The company has a market capitalization of $14.23 billion, a P/E ratio of 18.06, a P/E/G ratio of 1.73 and a beta of 0.42. The stock has a fifty day moving average of $55.34 and a 200-day moving average of $49.94.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.85 by $0.06. Exelixis had a net margin of 35.33% and a return on equity of 42.17%. The business had revenue of $628.69 million for the quarter, compared to the consensus estimate of $636.40 million. During the same period in the prior year, the company posted $0.75 earnings per share. Exelixis’s revenue was up 10.6% compared to the same quarter last year. On average, equities research analysts predict that Exelixis, Inc. will post 3.19 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on EXEL. Zacks Research raised Exelixis from a “strong sell” rating to a “hold” rating in a research report on Tuesday, September 1st. Citigroup restated a “market outperform” rating on shares of Exelixis in a report on Wednesday, July 22nd. Wall Street Zen lowered Exelixis from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Citizens Jmp raised their target price on shares of Exelixis from $50.00 to $55.00 and gave the stock a “market outperform” rating in a research note on Wednesday, June 24th. Finally, Weiss Ratings raised shares of Exelixis from a “buy (b)” rating to a “buy (a-)” rating in a report on Tuesday, August 11th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Exelixis presently has an average rating of “Hold” and a consensus target price of $50.07.

Insider Transactions at Exelixis

In other Exelixis news, Director Mary Beckerle sold 9,812 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $53.66, for a total value of $526,511.92. Following the completion of the sale, the director owned 16,079 shares of the company’s stock, valued at $862,799.14. The trade was a 37.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.60% of the stock is owned by corporate insiders.

Exelixis Company Profile

Exelixis, Inc (NASDAQ: EXEL) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. The company’s research and development activities center on targeted therapies designed to address biological pathways involved in tumor growth and progression.

Exelixis’ principal product is cabozantinib, marketed in the United States as CABOMETYX tablets for certain patients with advanced renal cell carcinoma, hepatocellular carcinoma and radioactive iodine-refractory differentiated thyroid cancer.